IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).

@inproceedings{Atkins2017IMmotion150AP,
  title={IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).},
  author={Michael B. Atkins and D F Mcdermott and Thomas Powles and Robert J Motzer and Brian I. Rini and Lawrence Fong and Richard W. Joseph and Sumanta Kumar Pal and Mario Sznol and John D Hainsworth and Walter M. Stadler and Thomas E. Hutson and Alain Ravaud and Sergio Bracarda and Cristina Su{\'a}rez and Toni K. Choueiri and Jiaheng Qiu and Mahrukh Huseni and Christina Schiff and Bernard Escudier},
  year={2017}
}
4505Background: While inhibiting VEGF improves outcomes in mRCC pts, most develop resistance, often within a year. Here, we report results from a Ph II study of atezo (anti–PD-L1) and bev (anti-VEGF) vs and following atezo or sun (TKI) in mRCC pts. Methods: Pts with untreated mRCC were enrolled in the hypothesis generating IMmotion150 study (NCT01984242) and randomized to atezo 1200 mg IV q3w + bev 15 mg/kg IV q3w, atezo alone or sun 50 mg PO QD 4 wk on/2 wk off. After progression on atezo or… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor‐1

  • Clinical and experimental immunology
  • 2018
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED